(Q36967274)

17 August 2017

1 reference

title

Pitavastatin: efficacy and safety in intensive lipid lowering (English)

1 reference

17 August 2017

Toshio Hayashi

1

1 reference

17 August 2017

Koutaro Yokote

series ordinal

2

1 reference

17 August 2017

Yasushi Saito

series ordinal

3

1 reference

17 August 2017

Akihisa Iguchi

series ordinal

4

1 reference

17 August 2017

language of work or name

English

0 references

publication date

1 October 2007

1 reference

Expert Opinion on Pharmacotherapy

17 August 2017

published in

1 reference

17 August 2017

volume

8

1 reference

17 August 2017

issue

14

1 reference

17 August 2017

page(s)

2315-2327

1 reference

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

17 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2315

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2315

Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2315

Gemfibrozil greatly increases plasma concentrations of cerivastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2315

Grapefruit juice-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2315

Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2315

High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2315

Pitavastatin: efficacy and safety profiles of a novel synthetic HMG-CoA reductase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2315

Structural mechanism for statin inhibition of HMG-CoA reductase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2315

Synthesis and biological evaluations of quinoline-based HMG-CoA reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2315

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2315

Enhanced oxidative stress in neutrophils from hyperlipidemic guinea pig.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2315

A new HMG-CoA reductase inhibitor, pitavastatin remarkably retards the progression of high cholesterol induced atherosclerosis in rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2315

Pitavastatin at low dose activates endothelial nitric oxide synthase through PI3K-AKT pathway in endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2315

MCP-1-induced enhancement of THP-1 adhesion to vascular endothelium was modulated by HMG-CoA reductase inhibitor through RhoA GTPase-, but not ERK1/2-dependent pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2315

Pitavastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, blocks vascular smooth muscle cell populated-collagen lattice contraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2315

Pitavastatin-induced thrombomodulin expression by endothelial cells acts via inhibition of small G proteins of the Rho family

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2315

Biphasic effect of HMG-CoA reductase inhibitor, pitavastatin, on vascular endothelial cells and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2315

Effect of pitavastatin on apolipoprotein A-I production in HepG2 cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2315

NK-104: a novel synthetic HMG-CoA reductase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2315

Effects of grapefruit juice on the pharmacokinetics of pitavastatin and atorvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2315

Uptake mechanism of pitavastatin, a new inhibitor of HMG-CoA reductase, in rat hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2315

Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase--effect of cMOAT deficiency on hepatobiliary excretion in rats and of mdr1a/b gene disruption on tissue distribution in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2315

A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2315

Long-term treatment with pitavastatin (NK-104), a new HMG-CoA reductase inhibitor, of patients with heterozygous familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2315

The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2315

Effect of pravastatin and atorvastatin on glucose metabolism in nondiabetic patients with hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2315

Acute onset and worsening of diabetes concurrent with administration of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2315

HMG-CoA reductase inhibitor decreases small dense low-density lipoprotein and remnant-like particle cholesterol in patients with type-2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2315

Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2315

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2315

A randomized, open-label study to evaluate the efficacy and safety of pitavastatin compared with simvastatin in Korean patients with hypercholesterolemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2315

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2315

Statin guidelines should give best statin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2315

Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2315

Efficacy of pitavastatin, a new HMG-CoA reductase inhibitor, on lipid and glucose metabolism in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2315

10.1517/14656566.8.14.2315

21 January 2018

Identifiers

DOI

1 reference

17 August 2017

1 reference